CJC-1295 isn't available on pharmacy shelves in Latur or virtually any local market — it's a research-grade peptide available through a dedicated online market. What this means for Latur researchers is that geography is secondary to your ability to assess COA data — and those verification methods are available to every researcher. A properly operating CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. The sections below cover what Latur researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Latur comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Vetting CJC-1295 vendors starts with the COA: access the batch-specific certificate before placing an order, not after. The HPLC purity trace is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be 98% or higher. Community reputation in research forums is a useful additional signal to COA verification — vendors with multi-year positive track records have proved themselves through consistent results. The powdered lyophilised form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Latur
COA-verified · International tracking · Research grade
All use of CJC-1295 in Latur or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution kept at 2-8°C refrigerated and used within 30 days; reconstitute only with sterile bacteriostatic water. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that proper COA verification addresses. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
